41
Participants
Start Date
December 31, 2012
Primary Completion Date
June 30, 2013
Study Completion Date
June 30, 2013
The COMBO Stent
The COMBO Stent is developed basing on the GENOUS stent platform, and in addition, it also delivers a drug called sirolimus to the treated coronary blood vessel. The stent's original CD34 antibody coating is designed to promote healing of the coronary artery by catching circulating endothelial progenitor cells as they pass through the stent. These cells are naturally flowing in the circulation and are responsible for endothelial healing. This is intended to help the blood vessel wall heal over the stent more quickly and restore normal tissue function in the stented area. The combination of these two technologies in this new COMBO stent is expected to produce even better clinical results, which have been investigated in the previous REMEDEE Study.
Department of Medicine, the University of Hong Kong, Queen Mary Hospital, Hospital Authority, Hong Kong
Prof. Stephen Lee
OTHER